Phase III, placebo-controlled, randomized, double-blind trial
image of papers

Date

Phase III, placebo-controlled, randomized, double-blind trial

Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month.

“Oral M. vaccae is safe, can overcome TB-associated weight loss and inflammation, reduce hepatotoxicity of TB drugs, improve sputum conversion three-fold OR 3.15; 95%CI (2.3,4.6), and cut treatment length by at least six-fold. Longer follow-up studies might be needed to further substantiate our findings (Clinicaltrials.gov: NCT01977768).”

https://pubmed.ncbi.nlm.nih.gov/31890902/

More
media

COVID-19 Oral Pill Therapeutic Vaccine Found Promising in Early Study

(Precision Vaccinations)
New York-based Key Capital Corporation announced independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for the safety and efficacy of the vaccine.

image of papers

Interim results

Interim results from ongoing Phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication.